What is BC Platforms?
BC Platforms operates at the intersection of advanced analytics and clinical research, providing a robust infrastructure for the management of complex genomic and clinical datasets. By specializing in data integration and privacy-preserving analytics, the company enables healthcare organizations to unlock actionable insights from disparate information sources. This capability is essential for the advancement of precision medicine, allowing researchers to accelerate drug discovery and improve patient outcomes through data-driven decision-making. As an enterprise-level player, BC Platforms serves a diverse clientele, including academic medical centers, biotech firms, and large-scale pharmaceutical enterprises, effectively bridging the gap between raw biological data and clinical application.
How much funding has BC Platforms raised?
BC Platforms has raised a total of $48.4M across 5 funding rounds:
Debt
$1.7M
Series A
$1.7M
Series B
$10M
Series C
$15M
Other Financing Round
$20M
Debt (2016): $1.7M, investors not publicly disclosed
Series A (2016): $1.7M led by Boston Millennia Partners
Series B (2017): $10M supported by Tesi
Series C (2019): $15M featuring IQVIA, Tesi, and Debiopharm Innovation Fund
Other Financing Round (2022): $20M backed by Jolt Capital
Key Investors in BC Platforms
Jolt Capital
Jolt Capital is a private equity firm that specializes in growth-stage deeptech companies, focusing on sectors such as cybersecurity, semiconductors, and advanced materials.
Tesi
Tesi (Finnish Industry Investment Ltd) is a venture capital and private equity company that accelerates companies' success stories by investing in them directly and via funds.
IQVIA
IQVIA is a global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find solutions for their patients.
What's next for BC Platforms?
With the infusion of recent capital, BC Platforms is well-positioned to accelerate its international expansion and enhance its technological stack. The strategic focus will likely center on deepening its integration with global healthcare ecosystems and refining its privacy-enhancing technologies to meet the increasing demand for secure, compliant data sharing. By leveraging its established partnerships with industry giants and specialized investment firms, the company is poised to solidify its dominance in the genomics analytics market. Future growth initiatives will likely prioritize the scaling of its platform to support larger, multi-center clinical trials and the development of new analytical modules that address the evolving complexities of personalized therapeutic development.
See full BC Platforms company page
